{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:06:22Z","timestamp":1790003182887,"version":"4.0.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T00:00:00Z","timestamp":1641168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T00:00:00Z","timestamp":1641168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Eribulin methylate (eribulin) improved the overall survival (OS) of eribulin-treated patients with HER2-negative advanced breast cancer (ABC) in prospective and retrospective studies. However, the effect of eribulin on OS as first-line chemotherapy and the characteristics of the patients who benefited from eribulin remain unclear.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Between January 2011 and December 2016, 301 patients with HER2-negative ABC who started first-line chemotherapy at 3 institutions were retrospectively evaluated for OS from the initiation of first-line chemotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We identified 172 patients (119 estrogen receptor-positive [ER+], 47 ER\u2212, 6 unknown) who received eribulin (eribulin group) and 129 patients (92 ER+, 31 ER\u2212, 6 unknown) who did not receive eribulin (non-eribulin group). The median OS from the initiation of first-line chemotherapy in the two groups was not statistically significant (869 vs. 744 days, <jats:italic>P<\/jats:italic> = 0.47, log-rank); however, in patients who received eribulin in later lines (\u22653rd-line) and who had a history of perioperative chemotherapy with anthracycline- and\/or taxane-based regimens, the median OS improved (1001 vs. 744 days, <jats:italic>P<\/jats:italic> = 0.037; and 834 vs. 464 days, respectively <jats:italic>P<\/jats:italic> = 0.032, respectively; Wilcoxon). Multivariate analyses revealed that a history of perioperative chemotherapy with anthracycline- and\/or taxane-based regimens was a predictive factor (hazard ratio, 0.39; 95% confidence interval, 0.21\u20130.70) for OS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study successfully identified subgroups of HER2\u2212 ABC patients with improved OS by eribulin therapy. Selecting patients according to their background and line of treatment will maximize the efficacy of eribulin therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-09137-0","type":"journal-article","created":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T10:05:23Z","timestamp":1641204323000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8043-8608","authenticated-orcid":false,"given":"Shogo","family":"Nakamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9226-895X","authenticated-orcid":false,"given":"Junichiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichiro","family":"Ohtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,3]]},"reference":[{"issue":"8","key":"9137_CR1","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","volume":"29","author":"F Cardoso","year":"2018","unstructured":"Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, Andr\u00e9 F, et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020. Ann Oncol. 2018;29(8):1634\u201357.","journal-title":"Ann Oncol"},{"issue":"29","key":"9137_CR2","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1200\/JCO.2014.56.7479","volume":"32","author":"AH Partridge","year":"2014","unstructured":"Partridge AH, Rumble RB, Carey LA, Come SE, Davidson NE, Di Leo A, et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2014;32(29):3307\u201329.","journal-title":"J Clin Oncol"},{"issue":"9769","key":"9137_CR3","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. The Lancet. 2011;377(9769):914\u201323.","journal-title":"The Lancet"},{"issue":"6","key":"9137_CR4","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","volume":"33","author":"PA Kaufman","year":"2015","unstructured":"Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015;33(6):594\u2013601.","journal-title":"J Clin Oncol"},{"issue":"3","key":"9137_CR5","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10549-014-3144-y","volume":"148","author":"C Twelves","year":"2014","unstructured":"Twelves C, Cortes J, Vahdat L, Olivo M, He Y, Kaufman PA, et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat. 2014;148(3):553\u201361.","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"9137_CR6","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1093\/annonc\/mdw203","volume":"27","author":"X Pivot","year":"2016","unstructured":"Pivot X, Marm\u00e9 F, Koenigsberg R, Guo M, Berrak E, Wolfer A. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Ann Oncol. 2016;27(8):1525\u201331.","journal-title":"Ann Oncol"},{"key":"9137_CR7","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1186\/s40064-015-1422-8","volume":"4","author":"J Watanabe","year":"2015","unstructured":"Watanabe J. Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional review. Springerplus. 2015;4:625.","journal-title":"Springerplus"},{"issue":"12","key":"9137_CR8","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1002\/ijc.32402","volume":"145","author":"W Jacot","year":"2019","unstructured":"Jacot W, Heudel PE, Fraisse J, Gourgou S, Guiu S, Dalenc F, et al. Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program. Int J Cancer. 2019;145(12):3359\u201369.","journal-title":"Int J Cancer"},{"key":"9137_CR9","doi-asserted-by":"crossref","unstructured":"Kazmi S, Chatterjee D, Raju D, Hauser R, Kaufman PA. Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine. Breast Cancer Res Treat. 2020.","DOI":"10.1007\/s10549-020-05867-0"},{"issue":"3","key":"9137_CR10","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.21873\/invivo.11917","volume":"34","author":"S Nakamoto","year":"2020","unstructured":"Nakamoto S, Watanabe J, Ohtani S, Morita S, Ikeda M. Bevacizumab as First-line Treatment for HER2-negative Advanced Breast Cancer: Paclitaxel plus Bevacizumab Versus Other Chemotherapy. In Vivo. 2020;34(3):1377\u201386.","journal-title":"In Vivo"},{"issue":"2","key":"9137_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"3","key":"9137_CR12","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"28","key":"9137_CR13","doi-asserted-by":"publisher","first-page":"7081","DOI":"10.1200\/JCO.2005.06.236","volume":"23","author":"M Bontenbal","year":"2005","unstructured":"Bontenbal M, Creemers GJ, Braun HJ, de Boer AC, Janssen JT, Leys RB, et al. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J Clin Oncol. 2005;23(28):7081\u20138.","journal-title":"J Clin Oncol"},{"issue":"24","key":"9137_CR14","doi-asserted-by":"publisher","first-page":"3950","DOI":"10.1200\/JCO.2007.11.9362","volume":"26","author":"KS Albain","year":"2008","unstructured":"Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A, et al. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008;26(24):3950\u20137.","journal-title":"J Clin Oncol"},{"issue":"8","key":"9137_CR15","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724\u201334.","journal-title":"N Engl J Med"},{"issue":"26","key":"9137_CR16","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666\u201376.","journal-title":"N Engl J Med"},{"issue":"23","key":"9137_CR17","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1093\/jnci\/djp369","volume":"101","author":"KR Broglio","year":"2009","unstructured":"Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst. 2009;101(23):1642\u20139.","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"9137_CR18","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/bjc.2016.122","volume":"114","author":"S Ueda","year":"2016","unstructured":"Ueda S, Saeki T, Takeuchi H, Shigekawa T, Yamane T, Kuji I, et al. In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab. Br J Cancer. 2016;114(11):1212\u20138.","journal-title":"Br J Cancer"},{"issue":"10","key":"9137_CR19","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/cas.12488","volume":"105","author":"Y Funahashi","year":"2014","unstructured":"Funahashi Y, Okamoto K, Adachi Y, Semba T, Uesugi M, Ozawa Y, et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci. 2014;105(10):1334\u201342.","journal-title":"Cancer Sci"},{"issue":"6","key":"9137_CR20","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1038\/bjc.2014.80","volume":"110","author":"T Yoshida","year":"2014","unstructured":"Yoshida T, Ozawa Y, Kimura T, Sato Y, Kuznetsov G, Xu S, et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br J Cancer. 2014;110(6):1497\u2013505.","journal-title":"Br J Cancer"},{"issue":"11","key":"9137_CR21","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1111\/cas.13392","volume":"108","author":"K Ito","year":"2017","unstructured":"Ito K, Hamamichi S, Abe T, Akagi T, Shirota H, Kawano S, et al. Antitumor effects of eribulin depend on modulation of the tumor microenvironment by vascular remodeling in mouse models. Cancer Sci. 2017;108(11):2273\u201380.","journal-title":"Cancer Sci"},{"issue":"1","key":"9137_CR22","first-page":"401","volume":"38","author":"S Kashiwagi","year":"2018","unstructured":"Kashiwagi S, Asano Y, Goto W, Takada K, Takahashi K, Hatano T, et al. Mesenchymal-epithelial Transition and Tumor Vascular Remodeling in Eribulin Chemotherapy for Breast Cancer. Anticancer Res. 2018;38(1):401\u201310.","journal-title":"Anticancer Res"},{"issue":"16","key":"9137_CR23","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1200\/JCO.2010.31.5374","volume":"29","author":"A Gennari","year":"2011","unstructured":"Gennari A, Stockler M, Puntoni M, Sormani M, Nanni O, Amadori D, et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol. 2011;29(16):2144\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"9137_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170634","volume":"12","author":"S Kashiwagi","year":"2017","unstructured":"Kashiwagi S, Asano Y, Goto W, Takada K, Takahashi K, Noda S, et al. Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer. PLoS One. 2017;12(2):e0170634.","journal-title":"PLoS One"},{"issue":"5","key":"9137_CR25","first-page":"2929","volume":"38","author":"W Goto","year":"2018","unstructured":"Goto W, Kashiwagi S, Asano Y, Takada K, Morisaki T, Fujita H, et al. Eribulin Promotes Antitumor Immune Responses in Patients with Locally Advanced or Metastatic Breast Cancer. Anticancer Res. 2018;38(5):2929\u201338.","journal-title":"Anticancer Res"},{"issue":"5","key":"9137_CR26","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.clbc.2018.03.002","volume":"18","author":"Y Miyagawa","year":"2018","unstructured":"Miyagawa Y, Araki K, Bun A, Ozawa H, Fujimoto Y, Higuchi T, et al. Significant Association Between Low Baseline Neutrophil-to-Lymphocyte Ratio and Improved Progression-free Survival of Patients With Locally Advanced or Metastatic Breast Cancer Treated With Eribulin But Not With Nab-Paclitaxel. Clin Breast Cancer. 2018;18(5):400\u20139.","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"9137_CR27","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10549-020-05626-1","volume":"181","author":"J Watanabe","year":"2020","unstructured":"Watanabe J, Saito M, Horimoto Y, Nakamoto S. A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience. Breast Cancer Research and Treatment. 2020;181(1):211\u201320.","journal-title":"Breast Cancer Research and Treatment"},{"issue":"4","key":"9137_CR28","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s12282-020-01067-2","volume":"27","author":"Y Miyoshi","year":"2020","unstructured":"Miyoshi Y, Yoshimura Y, Saito K, Muramoto K, Sugawara M, Alexis K, et al. High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician's choice-in the EMBRACE study. Breast Cancer. 2020;27(4):706\u201315.","journal-title":"Breast Cancer"},{"issue":"6","key":"9137_CR29","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.21873\/anticanres.15095","volume":"41","author":"S Nakamoto","year":"2021","unstructured":"Nakamoto S, Ikeda M, Kubo S, Yamamoto M, Yamashita T. Dynamic Changes in Absolute Lymphocyte Counts During Eribulin Therapy Are Associated With Survival Benefit. Anticancer Res. 2021;41(6):3109\u201319.","journal-title":"Anticancer Res"},{"issue":"1","key":"9137_CR30","doi-asserted-by":"publisher","first-page":"6328","DOI":"10.1038\/s41598-021-85948-2","volume":"11","author":"S Nakamoto","year":"2021","unstructured":"Nakamoto S, Ikeda M, Kubo S, Yamamoto M, Yamashita T, Notsu A. Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer. Sci Rep. 2021;11(1):6328.","journal-title":"Sci Rep"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-09137-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-09137-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-09137-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T10:08:09Z","timestamp":1641204489000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-09137-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,3]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["9137"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-09137-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,3]]},"assertion":[{"value":"12 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the institutional review boards of each participating institution (approval number: Fukuyama City Hospital: 359; Hiroshima City Hiroshima Citizens Hospital: 2019-73; and Shizuoka Cancer Center: T30-25). All procedures performed in studies that involved human participants were in accordance with the ethical standards of the institutional and\/or national research committees and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Informed consent was obtained in the form of an opt-out option on the hospital website from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Author Shogo Nakamoto has received lecture fees from Chugai Pharmaceuticals, Eisai Co., Ltd., and Taiho Pharmaceuticals outside the submitted work; Junichiro Watanabe has received lecture fees from AstraZeneca, Chugai Pharmaceuticals, Daiichi-Sankyo, Eisai Co., Ltd., Eli-Lilly, Novartis Pharma, Pfizer, and Taiho Pharmaceuticals outside the submitted work; Shoichiro Ohtani has received lecture fees from AstraZeneca, Chugai Pharmaceuticals, Eli-Lilly, and Pfizer outside the submitted work; Satoshi Morita has received lecture fees from Chugai Pharmaceuticals outside the submitted work; Masahiko Ikeda has received lecture fees from AstraZeneca, Chugai Pharmaceuticals, Daiichi-Sankyo, Eisai Co., Ltd., Eli-Lilly, Kyowa Kirin, Pfizer, Nippon Kayaku, Novartis, Mundipharma, Celltrion Healthcare, and Sawai Pharmaceuticals outside the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}